ALCMI and Sophos IRB Form Strategic Partnership to Advance Lung Cancer Research

SAN CARLOS, Calif., Oct. 8, 2026 /CourierPR/ -- The Addario Lung Cancer Medical Institute (ALCMI) and Sophos Institutional Review Board (IRB) have formed a strategic partnership aimed at advancing lung cancer clinical research. This collaboration brings together ALCMI's extensive international network of lung cancer research with Sophos IRB's specialized oncology-focused review expertise.

ALCMI, a nonprofit organization comprising 25 of the world's leading research institutions, has been dedicated to investigator-initiated lung cancer clinical trials. The partnership with Sophos IRB will provide ALCMI with the necessary regulatory oversight and ethical review to support its growing research portfolio. Through the partnership, Sophos IRB will support ALCMI's growing portfolio of lung cancer research with oncology-specialized IRB expertise and independent regulatory oversight. Together, the organizations share a commitment to advancing scientifically important research while maintaining the highest standards for participant protection and ethical review.

Sophos IRB was built specifically for the complexities of oncology research. Its IRB roster includes oncologists with expertise across multiple areas of cancer research, including lung cancer, and its operating model is designed to support complex protocols, multisite studies, and the regulatory demands associated with modern oncology clinical research.

ALCMI, an international nonprofit consortium comprising 25 of the world's premier oncology research institutions, partners with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated clinical trials. The nonprofit bridges the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating research projects.

Sophos IRB is the first independent, central Institutional Review Board dedicated to the ethical and regulatory review of oncology clinical research. With more than 144 years of combined oncology experience across its IRB roster, Sophos provides central IRB review and ongoing oversight for sponsors, CROs, institutions, and research sites.

The partnership is expected to streamline the regulatory process for ALCMI, allowing researchers to focus more on their work and less on administrative tasks. This collaboration is a significant step in advancing lung cancer research and ensuring the highest standards of participant protection and ethical review.

Through this strategic alliance, ALCMI and Sophos IRB aim to accelerate the pace of scientific discovery and improve patient outcomes in the fight against lung cancer.